文献速递肝病

表皮生长因子受体配体双调蛋白保护胆汁淤积性肝损伤并调节胆汁酸合成

The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis.
PubMed 文献 · Hepatology · 2019-03-04

本研究探讨双调蛋白(AREG)在胆汁淤积性肝损伤中的作用及其受胆汁酸调控的机制。在原发性胆汁性胆管炎和原发性硬化性胆管炎患者肝脏中AREG水平升高,两种小鼠胆汁淤积模型中肝AREG表达上调,Areg-/-小鼠损伤加重,重组AREG可保护并减少胆汁酸诱导的肝细胞凋亡,胆汁酸经FXR促进AREG表达及蛋白脱落,AREG-EGFR信号参与胆汁酸合成调控。

要点

  • 胆汁淤积患者肝脏及小鼠模型中肝双调蛋白(AREG)表达升高。
  • Areg-/-小鼠胆汁淤积性肝损伤加重,重组AREG可减轻损伤及胆汁酸诱导的肝细胞凋亡。
  • 胆汁酸经FXR促进AREG表达与蛋白脱落,AREG-EGFR信号参与Cyp7a1抑制调控。

核心结论

  • AREG-EGFR信号可保护胆汁淤积性肝损伤并参与胆汁酸合成的生理性调控。

研究设计与样本

  • 研究检测原发性胆汁性胆管炎(PBC)和原发性硬化胆管炎(PSC)患者肝脏AREG水平。
  • 使用胆管结扎(BDL)和α-萘基异硫氰酸酯(ANIT)灌胃两种小鼠胆汁淤积性肝损伤模型。
  • 对比Areg-/-与Areg+/+小鼠,并测试重组AREG、口服胆汁酸及考来烯胺喂养的影响。
  • 在Fxr-/-小鼠及肝细胞中探讨胆汁酸调控AREG表达的机制。

主要发现

  • PBC和PSC患者肝脏AREG水平升高。
  • BDL和ANIT处理后小鼠肝脏AREG表达明显上调。
  • Areg-/-小鼠在BDL和ANIT后肝损伤较Areg+/+小鼠加重。
  • 重组AREG可保护ANIT和BDL诱导的肝损伤,并减少胆汁酸触发的肝细胞凋亡。
  • 口服胆汁酸诱导回肠和肝脏Areg表达,考来烯胺喂养减少两组织餐后Areg上调。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intrahepatic accumulation of bile acids (BAs) causes hepatocellular injury. Upon liver damage, a potent protective response is mounted to restore the organ's function. Epidermal growth factor receptor (EGFR) signaling is essential for regeneration after most types of liver damage, including cholestatic injury. However, EGFR can be activated by a family of growth factors induced during liver injury and regeneration. We evaluated the role of the EGFR ligand, amphiregulin (AREG), during cholestatic liver injury and regulation of AREG expression by BAs. First, we demonstrated increased AREG levels in livers from patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). In two murine models of cholestatic liver injury, bile duct ligation (BDL) and alpha-naphthyl-isothiocyanate (ANIT) gavage, hepatic AREG expression was markedly up-regulated. Importantly, Areg-/- mice showed aggravated liver injury after BDL and ANIT administration compared to Areg+/+ mice. Recombinant AREG protected from ANIT and BDL-induced liver injury and reduced BA-triggered apoptosis in liver cells. Oral BA administration induced ileal and hepatic Areg expression, and, interestingly, cholestyramine feeding reduced postprandial Areg up-regulation in both tissues. Most interestingly, Areg-/- mice displayed high hepatic cholesterol 7 α-hydroxylase (CYP7A1) expression, reduced serum cholesterol, and high BA levels. Postprandial repression of Cyp7a1 was impaired in Areg-/- mice, and recombinant AREG down-regulated Cyp7a1 mRNA in hepatocytes. On the other hand, BAs promoted AREG gene expression and protein shedding in hepatocytes. This effect was mediated through the farnesoid X receptor (FXR), as demonstrated in Fxr-/- mice, and involved EGFR transactivation. Finally, we show that hepatic EGFR expression is indirectly induced by BA-FXR through activation of suppressor of cytokine signaling-3 (SOC3). Conclusion: AREG-EGFR signaling protects from cholestatic injury and participates in the physiological regulation of BA synthesis.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Santamaría E, Rodríguez-Ortigosa CM, Uriarte I, et al. The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis. Hepatology. 2019. PMID: 30411380. doi:10.1002/hep.30348

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。